Cavendish Bio Pharma Profile
Key Indicators
- Authorised Capital ₹ 9.00 M
as on 24-10-2024
- Paid Up Capital ₹ 9.00 M
as on 24-10-2024
- Company Age 19 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.80 Cr
as on 24-10-2024
- Satisfied Charges ₹ 7.50 M
as on 24-10-2024
- Revenue -38.83%
(FY 2023)
- Profit -86.25%
(FY 2023)
- Ebitda -176.36%
(FY 2023)
- Net Worth 0.49%
(FY 2023)
- Total Assets -12.16%
(FY 2023)
About Cavendish Bio Pharma
The Company is engaged in the Machinery And Equipment Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 9.00 M and a paid-up capital of Rs 9.00 M.
The company currently has active open charges totaling ₹1.80 Cr. The company has closed loans amounting to ₹7.50 M, as per Ministry of Corporate Affairs (MCA) records.
Jagminder Singh and Manav Singh serve as directors at the Company.
- CIN/LLPIN
U24234TN2005PTC057399
- Company No.
057399
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
05 Sep 2005
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- LocationChennai 600017, Tamil Nadu
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Cavendish Bio Pharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Jagminder Singh  | Director | 01-Apr-2013 | Current |
| Manav Singh | Director | 07-May-2013 | Current |
Financial Performance of Cavendish Bio Pharma.
Cavendish Bio Pharma Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 38.83% decrease. The company also saw a substantial fall in profitability, with a 86.25% decrease in profit. The company's net worth moved up by a moderate rise of 0.49%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Cavendish Bio Pharma?
In 2023, Cavendish Bio Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Thrift Pharmaceuticals Private LimitedActive 28 years 5 monthsJagminder Singh and Manav Singh are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Yes Bank Limited Creation Date: 15 Dec 2016 | ₹1.00 Cr | Open |
Yes Bank Limited Creation Date: 13 Mar 2015 | ₹8.00 M | Open |
Punjab National Bank Creation Date: 26 Feb 2010 | ₹1.50 M | Satisfied |
How Many Employees Work at Cavendish Bio Pharma?
Cavendish Bio Pharma has a workforce of 6 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Cavendish Bio Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Cavendish Bio Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
